**G.S.K. Velu’s Maxivision Eyes West India Push Ahead of Listing Next Year**
G.S.K. Velu, the driving force behind Maxivision Eye Hospitals, is setting his sights on expanding the company’s presence in western India, just as he prepares for a highly anticipated listing next year.
Velu’s ambitions for Maxivision come as he chairs Neuberg Diagnostics, a diagnostic chain that is expected to be the first to list in the coming months. Neuberg’s IPO is likely to kick-start the process, paving the way for Maxivision and another medtech firm, Trivitron Healthcare, which Velu also chairs, to follow suit.
These listings are expected to materialize from calendar year **2027 onwards**, marking a significant milestone for the companies involved.
For Velu, the strategy behind Maxivision’s west India push is rooted in his vision for the company as a long-term legacy business. He’s quoted as saying: “For me, these are all long-term legacy businesses.”
While the exact details of Maxivision’s plans for western India remain unclear, the move is undoubtedly a significant one. The region has seen a surge in demand for eye care services in recent years, driven by factors such as increasing awareness about eye health and the growing prevalence of age-related diseases like cataracts and glaucoma.
**Key Takeaways**
* G.S.K. Velu’s Maxivision Eye Hospitals is planning to expand its presence in western India.
* The company’s listing is expected to take place next year, following Neuberg Diagnostics’ IPO.
* Maxivision’s west India push is part of the company’s long-term strategy to establish itself as a legacy business.
**What This Means**
For consumers in western India, Maxivision’s expansion is likely to bring more accessible and high-quality eye care services to the region. As the company establishes a stronger presence, it may also drive down costs and increase competition, ultimately benefiting patients.
